UniQuest: Ledger

Stories naming UniQuest. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
Founder	Vaxxas	Brandon Capital portfolio (Thu 19 Jan 2023), Brandon Capital portfolio (Wed 9 Nov 2022)

Unnamed stage

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)

Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch; the article also recalls the company's founding financing led by OneVentures with Brandon Capital and other co-investors.

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au

UniQuest

Roles

Coverage

Coming in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)